FIMASARTAN POTASSIUM TRIHYDRATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C27H30N7OS.K.3H2O
Molecular Weight	593.783
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of FIMASARTAN POTASSIUM TRIHYDRATE

Structure Search

SMILES

O.O.O.[K+].CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=N[N-]4

InChI

InChIKey=IJEKJHQBGZFMMI-UHFFFAOYSA-N

InChI=1S/C27H30N7OS.K.3H2O/c1-5-6-11-24-28-18(2)23(16-25(36)33(3)4)27(35)34(24)17-19-12-14-20(15-13-19)21-9-7-8-10-22(21)26-29-31-32-30-26;;;;/h7-10,12-15H,5-6,11,16-17H2,1-4H3;;3*1H2/q-1;+1;;;

HIDE SMILES / InChI

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C27H31N7OS
Molecular Weight	501.646
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	K
Molecular Weight	39.0983
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22864732
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23811571, http://www.boryung.co.kr/eng/product/mainProduct.do

Fimasartan is a angiotensin II receptor antagonist which was developed in Korea for the treatment of hypertension. The drug is available in different forms: Kanarb, Dukarb (in combination with Amlodipine), Tuvero (in combination with Rosuvastatin). Fimasartan was tested to be effective in Mexican and Russian population and now is being tested in the USA.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Angiotensin II receptor 9 Target ID: CHEMBL2094256 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23811571	Antagonist 2778		0.13 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Essential hypertension 17 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22864732	Primary		Approved 8429	KANARB Approved Use For the treatment of essential hypertension. Launch Date 1.28329921E12

PubMed

Title	Date	PubMed
Fimasartan, anti-hypertension drug, suppressed inducible nitric oxide synthase expressions via nuclear factor-kappa B and activator protein-1 inactivation.	2013	23449332
Influence of Fimasartan (a Novel AT(1) Receptor Blocker) on Catecholamine Release in the Adrenal Medulla of Spontaneously Hypertensive Rats.	2013 Feb	23441003
Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study.	2014	25336916

Patents

Sample Use Guides

In Vivo Use Guide

Fimasartan is taken as a single oral dose of 60-mg tablet or a single 30-mg intravenous (IV) infusion.

Route of Administration: Other

In Vitro Use Guide

Rabbit thoracic aorta cells were incubated with different concentrations of fimasartan ((0.1, 1, 10 nM). At those concentrations fimasartan caused nonparallel rightward shifts in the concentration–contractile response curve to Ang II with a significant reduction in the maximal contractile response to 96.6, 47 and 18%, respectively.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 08:10:40 UTC 2023` Edited by `admin` on `Sat Dec 16 08:10:40 UTC 2023`
Record UNII	4516BN0T4B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FIMASARTAN POTASSIUM TRIHYDRATE

Common Name

English

5-PYRIMIDINEETHANETHIOAMIDE, 2-BUTYL-1,6-DIHYDRO-N,N,4-TRIMETHYL-6-OXO-1-((2'-(2H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-, POTASSIUM SALT, HYDRATE (1:1:3)

Systematic Name

English

BR-A-657

Code

English

Fimasartan potassium trihydrate [WHO-DD]

Common Name

English

Code System Code Type Description

DRUG BANK

DBSALT001281